Impact of Maternal Asthma and Asthma Treatment During Pregnancy on Neurodevelopmental Outcomes: Findings from a Cohort Study of 179,024 Children - Scorecard - MDSpire

Impact of Maternal Asthma and Asthma Treatment During Pregnancy on Neurodevelopmental Outcomes: Findings from a Cohort Study of 179,024 Children

  • By

  • Lama A. Shakhshir

  • Sarjit Singh

  • Jill P. Pell

  • Scott M. Nelson

  • Daniel F. Mackay

  • Claire E. Hastie

  • Logesh R. Sivakumar

  • Michael Fleming

  • February 20, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Maternal Asthma and Asthma Treatment During Pregnancy on Neurodevelopmental Outcomes: Findings from a Cohort Study of 179,024 Children

At a Glance

CategoryDetail
ConditionMaternal Asthma
Key MechanismsAsthma exacerbations during pregnancy and treatment with asthma medications.
Target PopulationPregnant women with asthma and their children.
Care SettingMaternity and pediatric care.

Key Highlights

  • Asthma prevalence among pregnant women is 8–13%.
  • B2AA and ICS are considered safe for maternal and perinatal outcomes.
  • Potential associations between prenatal asthma treatment and neurodevelopmental disorders like ADHD and ASD.
  • Study included a large cohort of 179,024 children born in Wales.
  • Primary outcome was the record of special educational needs (SEN) in children.

Guideline-Based Recommendations

Diagnosis

  • Asthma defined by eligible Read codes recorded within 2 years prior to delivery.

Management

  • Continuation of asthma medication during pregnancy is recommended.

Monitoring & Follow-up

  • Children's neurodevelopmental outcomes should be monitored, especially for SEN.

Risks

  • Uncontrolled asthma poses risks to both maternal and fetal health.

Patient & Prescribing Data

179,024 children born to mothers registered with SAIL general practitioners.

12.4% of mothers had a record of asthma or asthma medication.

Clinical Best Practices

  • Utilize B2AA as first-line treatment for asthma in pregnancy.
  • Monitor for asthma exacerbations and adjust treatment as necessary.
  • Consider potential neurodevelopmental outcomes when prescribing asthma medications.

References

Original Source(s)

Related Content